Exagen Inc. to Participate in Upcoming Investor Conferences
Exagen (NASDAQ:XGN) had its price target lowered by analysts at TD Cowen from $13.00 to $10.00. They now have a "buy" rating on the stock.
Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026 [Yahoo! Finance]
Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
Exagen (NASDAQ:XGN) had its price target lowered by analysts at BTIG Research from $15.00 to $10.00. They now have a "buy" rating on the stock.